CCI
ACAD icon

Columbus Circle Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Columbus Circle Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,600
Closed -$324K – 178
2017
Q3 		$324K Buy
+8,600
New +$280K 0.01% 281

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Columbus Circle Investors's ACAD Position: Q3 2020 in Review

Columbus Circle Investors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 409,102 shares — an estimated $19.8M sold.

Columbus Circle Investors first reported a position in ACAD in Q4 2013 and held it in 11 quarters. The position peaked at $19.8M in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Columbus Circle Investors reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Columbus Circle Investors sold 409,102 Acadia Pharmaceuticals shares in Q3 2020, an estimated $19.8M.
  • Columbus Circle Investors first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 11 quarters.
  • Columbus Circle Investors's Acadia Pharmaceuticals position peaked at $19.8M in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Columbus Circle Investors's 13F filing for Q3 2020, filed 27 Oct 2020.